[1] [1] NANITA M. Pathogenesis of extrapulmonary manifestations of Mycoplasma pneumoniae infection with special reference to pneumonia ［J］. Journal of Infection & Chemotherapy, 2010, 16(3): 162.

[2] [2] MANILOFF J, MCELHANEY R N, FINCH L R, et al. Mycoplasmas: molecular biology and pathogenesis ［M］. Washington: American Society for Microbiology, 1992.

[3] [3] FERWERDA A, MOLL H A, GROOT R D. Respiratory tract infections by Mycoplasma pneumoniae in children: a review of diagnostic and therapeutic measures ［J］. European Journal of Pediatrics, 2001, 160(8): 483-491.

[4] [4] SENOSIAIN M, DOMINGO-GORDO B, FERNáNDEZ C, et al. Neuro-ophthalmological manifestations as complication of an infection with Mycoplasma pneumoniae and subsequent development of disseminated acute encephalitis ［J］. Archivos de la Sociedad Espanola de Oftalmologia, 2020, 95(5): 254-258.

[5] [5] WADE C I, EARLEY K E, JUSTIN G A, et al. Vogt-koyanagi-harada disease presenting secondary to a post-infectious Mycoplasma pneumoniae autoimmune response ［J］. Ophthalmology Case Reports, 2020, 19: 100793.

[6] [6] PARROTT G L, TAKESHI K, JIRO F. A compendium for Mycoplasma pneumoniae ［J］. Frontiers in Microbiology, 2016, 7: 513.

[7] [7] INBAL L, EYAL K, RAN N P. Mycoplasma pneumoniae vaccine protective efficacy and adverse reactions—systematic review and meta-analysis ［J］. Vaccine, 2009, 27(18): 2437-2446.

[9] [9] WOLFF B J, BENITEZ A J, DESAI H P, et al. Development of a multiplex taqMan real-time PCR assay for typing of Mycoplasma pneumoniae based on type-specific indels identified through whole genome sequencing［J］. Diagnostic Microbiology ＆ Infections Disease, 2017, 87(3): 203-206.

[10] [10] DANDEKAR T, HUYNEN M, REGULA J T, et al. Re-annotating the Mycoplasma pneumoniae genome sequence: adding value, function and reading frame ［J］. Nuclc Acids Research, 2000, 28(17): 3278-3288.

[11] [11] SCHEFFER M P, GONZALEZ-GONZALEZ L, SEYBERT A, et al. Structural characterization of the NAP; the major adhesion complex of the human pathogen mycoplasma genitalium ［J］. Molecular Microbiology, 2017, 105(6): 869-879.

[12] [12] KRAUSE D C. Mycoplasma pneumoniae cytadherence: unravelling the tie that binds ［J］. Molecular Microbiology, 2010, 20(2): 247-253.

[13] [13] SETO S, KENRI T, TOMIYAMA T, et al. Involvement of P1 adhesin in gliding motility of Mycoplasma pneumoniae as revealed by the inhibitory effects of antibody under optimized gliding conditions ［J］. Journal of Bacteriology, 2005, 187(5): 1875-1877.

[14] [14] HU P, COLE R, HUANG Y, et al. Mycoplasma pneumoniae infection: role of a surface protein in the attachment organelle ［J］. Sence, 1982, 216(4543): 313-315.

[15] [15] KRAUSE D C, LEITH D K, WILSON R M, et al. Identification of Mycoplasma pneumoniae proteins associated with hemadsorption and virulence ［J］. Infection & Immunity, 1982, 35(3): 809-817.

[16] [16] JACOBS E, PILATSCHEK A, GERSTENECKER B, et al. Immunodominant epitopes of the adhesin of Mycoplasma pneumoniae ［J］. Journal of Clinical Microbiology, 1990, 28(6): 1194-1197.

[17] [17] SPERKER B, HU P C, HERRMANN R. Identification of gene products of the P1 operon of Mycoplasma pneumonia ［J］. Molecular Microbiology, 2010, 5(2): 299-306.

[18] [18] VIZARRAGA D, KAWAMOTO A, MATSUMOTO U, et al. Immunodominant proteins P1 and P40/P90 from human pathogen Mycoplasma pneumoniae ［J］. Nature Communications, 2020, 11(1): 1-16.

[19] [19] HASSELBRING B M, KRAUSE D C. Proteins P24 and P41 function in the regulation of terminal-organelle development and gliding motility in mycoplasma pneumonia ［J］. Journal of Bacteriology, 2007, 189(20): 7442.

[20] [20] PILO P, VILEI E M, PETERHANS E, et al. A metabolic enzyme as a primary virulence factor of Mycoplasma mycoides subsp. mycoides small colony ［J］. Journal of Bacteriology, 2005, 187(19): 6824-6831.

[21] [21] LOW I E. Effect of medium on H(2)O(2) levels and peroxidase-like activity by Mycoplasma pneumonia ［J］. Infection and Immunity, 1971, 3(1): 80-86.

[22] [22] ALMAGOR M, KAHANE I, YATZIV S. Role of superoxide anion in host cell injury induced by Mycoplasma pneumoniae infection: a study in normal and trisomy 21 cells ［J］. Journal of Clinical Investigation, 1984, 73(3): 842-847.

[23] [23] TRYON V V, BASEMAN J B. The acquisition of human lactoferrin by Mycoplasma pneumoniae ［J］. Microbial Pathogenesis, 1987, 3(6): 437-443.

[24] [24] RHEE S G, KANG S W, JEONG W, et al.??Intracellular messenger function of hydrogen peroxide and its regulation by peroxiredoxins ［J］. Current Opinion in Cell Biology, 2005, 17(2): 183-189.

[25] [25] KRAUSE D C, CHEN Y Y. Interaction of Mycoplasma pneumoniae with HeLa cells ［J］. Infection & Immunity, 1988, 56(8): 2054-2059.

[26] [26] DALLO S F, BASEMAN J B. Intracellular DNA replication and long-term survival of pathogenic mycoplasmas ［J］. Microbial Pathogenesis, 2000, 29(5): 301-309.

[27] [27] BOSE S, SEGOVIA J A, SOMARAJAN S R, et al. ADP-ribosylation of NLRP3 by Mycoplasma pneumoniae cards toxin regulates inflammasome activity ［J］. Microbiology, 2014, 5(6):1-11.

[28] [28] MEDINA J L, COALSON J J, BROOKS E G, et al. Mycoplasma pneumoniae cards toxin induces pulmonary eosinophilic and lymphocytic inflammation ［J］. American Journal of Respiratory Cell and Molecular Biology, 2012, 46(6): 815-822.

[29] [29] ZHAO Y, MA G, YANG X. HDAC5 promotes Mycoplasma pneumoniae-induced inflammation in macrophages through NF-κB activation ［J］. Life Sciences, 2019, 221: 13-19.

[30] [30] NAGHIB M, JAHROMI M H, NIKTAB M, et al. Mycoplasma pneumoniae and toll-like receptors: a mutual avenue ［J］. Allergologia et Immunopathologia, 2018, 46: 508-513.

[31] [31] HUGHES R A C, HADDEN R D M, GREGSON N A, et al. Pathogenesis of guillain-barre syndrome ［J］. Journal of the Peripheral Nervous System, 2010, 5(1/2): 122-123.

[32] [32] DAXBOECK F, BLACKY A, SEIDL R, et al. Diagnosis, treatment, and prognosis of Mycoplasma pneumoniae childhood encephalitis: systematic review of 58 cases ［J］. Journal of Child Neurology, 2004, 19(11): 865-871.

[33] [33] CHRISTIE L J, HONARMAND S, TALKINGTON D F, et al. Pediatric encephalitis: what is the role of Mycoplasma pneumoniae? ［J］. Pediatrics, 2007, 120(2): 305.

[34] [34] CHAPLIN D D, ZINDL C L, ATKINSON T P, et al. Effector and regulatory roles of distinct lung macrophage subsets in the response to Mycoplasma pneumoniae in hosts with allergic airway inflammation ［J］. Journal of Allergy and Clinical Immunology, 2012, 129(2): 367.

[35] [35] YANG J, HOOPER W C, PHILLIPS D J, et al. Regulation of proinflammatory cytokines in human lung epithelial cells infected with Mycoplasma pneumoniae ［J］. Infection and Immunity, 2002, 70(7): 3649-3655.

[36] [36] KRISTEN L, LYNN B, GAIL H, et al. A role for the Mycoplasma pneumoniae adhesin P1 in interleukin (IL)-4 synthesis and release from rodent mast cells ［J］. Microbial Pathogenesis, 2005, 39(4): 149-158.

[37] [37] YANG J, HOOPER W C, PHILLIPS D J, et al. Interleukin-1beta responses to Mycoplasma pneumoniae infection are cell-type specific ［J］. Microbial Pathogenesis, 2003, 34(1): 17-25.

[38] [38] JOANNE G, INES S, BREGJE J, et al. Neonate with mycoplasma hominis meningoencephalitis given moxifloxacin ［J］. The Lancet Infectious Diseases, 2016, 16(11): 261-266.

[39] [39] SARAYA T, NAKATA K, NAKAGAKI K, et al. Identification of a mechanism for lung inflammation caused by Mycoplasma pneumoniae using a novel mouse model ［J］. Results in Immunology, 2011, 1(1): 76-87.

[40] [40] DAISUKE N, TSUYOSHI K, LISA M, et al. Systematic structural analyses of attachment organelle in Mycoplasma pneumoniae ［J］. PLoS Pathogens, 2015, 11(12):1-19.

[41] [41] SMITH-NOROWITZ T A, SILVERBERG J I, KUSONRUKSA M, et al. Asthmatic children have increased specific anti-Mycoplasma pneumoniae IgM but not IgG or IgE—values independent of history of respiratory tract infection ［J］. Pediatric Infectious Disease Journal, 2013, 32(6): 599-603.

[42] [42] BEERSMA M F, DIRVEN K, VAN DAM A P,?et al. Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the “gold standard” ［J］. Journal of clinical microbiology, 2005, 43(5): 2277-2285.

[45] [45] WAITES K B, TALKINGTON D F.?Mycoplasma pneumoniae and its role as a human pathogen ［J］. Clinical Microbiology Reviews, 2004, 17(4): 697-728.

[46] [46] BARILE M F. Mycoplasma-tissue cell interactions ［M］. New York: The Mycoplasmas, 1979.

[47] [47] RAZIN S, YOGEV D, NAOT Y. Molecular biology and pathogenicity of mycoplasmas ［J］. Microbiology and Molecular Biology Reviews, 1998, 62(4): 1094-1156.

[48] [48] WAITES K B, CHRISTIANE B, ROBERTSON J A, et al. Laboratory diagnosis of mycoplasmal and ureaplasmal infections ［J］. Clinical Microbiology Newsletter, 1996, 18(14): 105-112.

[50] [50] OKUBO Y, MICHIHATA N, MORISAKI N, et al. Recent trends in practice patterns and impact of corticosteroid use on pediatric Mycoplasma pneumoniae-related respiratory infections ［J］. Respiratory Investigation, 2017, 56(2): 158-165.

[51] [51] SIM J Y, CHANG Y H, CHEN W Y, et al. Severe Mycoplasma pneumoniae infections with prolonged fever in a child: delayed treatment is as important as macrolide resistance ［J］. Immunology and Infection, 2020, 4(4): 1-3.

[52] [52] WAGNER K, IMKAMP F, PIRES V P, et al. Evaluation of the lightmix mycoplasma macrolide assay for the detection of macrolide resistant Mycoplasma pneumoniae in pneumonia patients ［J］. Clinical Microbiology and Infection, 2018, 25(3): 383.e5-383.e7.

[53] [53] LINCHEVSKI I, KLMENET E, NIR-PAZ R. Mycoplasma pneumoniae vaccine protective efficacy and adverse reactions—systematic review and meta-analysis ［J］. Vaccine, 2009, 27(18): 2437-2446.

[54] [54] SMITH C B, FRIEDEWALD W T, CHANOCK R M. Inactivated Mycoplasma pneumoniae vaccine ［J］. Jama, 1967, 199(6): 353.

[55] [55] SZCZEPANEK S M, MAJUMDER S, SHEPPARD E S, et al. Vaccination of BALB/c mice with an avirulent Mycoplasma pneumoniae P30 mutant results in disease exacerbation upon challenge with a virulent strain ［J］. Infection & Immunity, 2012, 80(3): 1007.

[57] [57] BISHWANATH K, RAMA C, PAWAN M, et al. Delineation of immunodominant and cytadherence segment(s) of Mycoplasma pneumoniae P1 gene ［J］. BMC Microbiology, 2014, 14(1): 108.

[58] [58] TAMIYA S, YOSHIKAWA E, OGURA M, et al. Vaccination using inactivated Mycoplasma pneumoniae induces detrimental infiltration of neutrophils after subsequent infection in mice ［J］. Vaccine, 2020, 38(32): 4979-4987.